Pb1829: Argentinean Real World Experience on Midostaurin Plus Intensive Chemotherapy vs Intensive Chemotherapy to Treat Flt3 Positive Acute Myeloid Leukemia Patients

Abstract

Background: Background:Midostaurin has been approved by EMA and FDA in combination with intensive chemotherapy (CMT) for FLT3 positive AML based on improved survival. In Argentine was included among therapy strategies in 2018. The realworld experience in day-to-day practice is limited.